Bernardini S, Adessi G L, Billerey C, Chezy E, Carbillet J P, Bittard H
Department of Molecular Oncology-Endocrinology, Centre Hospitalo-Universitaire, Besançon, France.
J Urol. 1999 Oct;162(4):1496-501.
PURPOSE: Mutations of p53 tumor suppressor gene and nuclear accumulation of p53 protein are common in bladder tumors. The prognostic significance of p53 alterations in bladder tumors has not been established. The aim of the present study was to evaluate an immunohistochemical (IHC) method for the routine determination of p53 protein overexpression in human bladder tumors and to determine the relation between nuclear accumulation of p53 with the traditional prognostic indicators and patient survival. MATERIALS AND METHODS: 104 transitional cell carcinomas of the bladder were analyzed simultaneously by immunohistochemistry for p53 protein overexpression and direct DNA sequencing for p53 gene mutations. RESULTS: The overexpression of p53 protein was reported in 30.8% of the cases and mutations of p53 gene in 23.0%. A significant association was observed between p53 alterations established either by IHC or direct DNA sequencing and stage (p<0.0001), grade (p<0.001), vascular invasion (p = 0.0005), DNA ploidy (p = 0.0002) and carcinoma in situ (p<0.0001). The correlation between the p53 gene mutations and p53 nuclear reactivity as detected by IHC was highly significant (p<0.0001). Univariate statistical analysis showed that the expression of p53 was significantly correlated to poor prognosis (p<0.0001). However, in multivariate analysis, only stage was significantly correlated to prognosis (p<0.0001). CONCLUSIONS: The IHC method was highly sensitive and specific and simple to apply for the routine examination of p53 overexpression in bladder tumors. However, overexpression of p53 as determined immunohistochemically, does not appear to have a better predictive prognostic value than stage in bladder tumors.
目的:p53肿瘤抑制基因的突变和p53蛋白的核内积聚在膀胱肿瘤中很常见。p53改变在膀胱肿瘤中的预后意义尚未确定。本研究的目的是评估一种免疫组织化学(IHC)方法,用于常规测定人膀胱肿瘤中p53蛋白的过表达,并确定p53核内积聚与传统预后指标及患者生存率之间的关系。 材料与方法:对104例膀胱移行细胞癌同时进行免疫组织化学分析以检测p53蛋白的过表达,并进行直接DNA测序以检测p53基因突变。 结果:30.8%的病例报告有p53蛋白过表达,23.0%有p53基因突变。通过免疫组织化学或直接DNA测序确定的p53改变与分期(p<0.0001)、分级(p<0.001)、血管侵犯(p = 0.0005)、DNA倍体(p = 0.0002)和原位癌(p<0.0001)之间存在显著关联。免疫组织化学检测到的p53基因突变与p53核反应性之间的相关性非常显著(p<0.0001)。单因素统计分析表明,p53的表达与预后不良显著相关(p<0.0001)。然而,在多因素分析中,只有分期与预后显著相关(p<0.0001)。 结论:免疫组织化学方法高度敏感、特异且易于应用于膀胱肿瘤中p53过表达的常规检查。然而,免疫组织化学测定的p53过表达在膀胱肿瘤中似乎没有比分期更好的预测预后价值。
J Urol. 1998-4
N Engl J Med. 1994-11-10
Int Med Case Rep J. 2019-6-28
Int J Clin Exp Pathol. 2014-10-15
Nat Rev Urol. 2011-8-2